Real World Use of Anti-Obesity Medications and Weight Change in Veterans.

Hung A, Wong ES, Dennis PA, Stechuchak KM, Blalock DV, Smith VA, Hoerster K, Vimalananda VG, Raffa SD, Maciejewski ML. Real World Use of Anti-Obesity Medications and Weight Change in Veterans. Journal of general internal medicine. 2023 Nov 14.

Related HSR&D Project(s)

• CDA 19-035 – Telehealth Treatment of Veterans with Alcohol Misuse at Risk for Cardiovascular Disease
• IIR 18-019 – Measuring the Longitudinal Relationshipsbetween Obesity, Weight Management Intervention, and Medical Expenditure
• CDA 20-273 – Helping Veterans Navigate Dual Pharmacy Benefits

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information vaww.hsrd.research.va.gov/dimensions/

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.    Search Dimensions for VA for this citation
* Don't have VA-internal network access or a VA email address? Try searching the free-to-the-public version of Dimensions

Search for Abstract from PubMed

---

Abstract:

BACKGROUND: Anti-obesity medications (AOMs) can be initiated in conjunction with participation in the VA national behavioral weight management program, MOVE!, to help achieve clinically meaningful weight loss. OBJECTIVE: To compare weight change between Veterans who used AOM?+?MOVE! versus MOVE! alone and examine AOM use, duration, and characteristics associated with longer duration of use. DESIGN: Retrospective cohort study using VA electronic health records. PARTICIPANTS: Veterans with overweight or obesity who participated in MOVE! from 2008-2017. MAIN MEASURES: Weight change from baseline was estimated using marginal structural models up to 24 months after MOVE! initiation. The probability of longer duration of AOM use ( = 180 days) was estimated via a generalized linear mixed model. RESULTS: Among MOVE! participants, 8,517 (1.6%) used an AOM within 24 months after MOVE! initiation with a median of 90 days of cumulative supply. AOM?+?MOVE! users achieved greater weight loss than MOVE! alone users at 6 (3.2% vs. 1.6%, p? < 0.001), 12 (3.4% vs. 1.4%, p? < 0.001), and 24 months (2.7% vs. 1.5%, p? < 0.001), and had a greater probability of achieving? = 5% weight loss at 6 (38.8% vs. 26.0%, p? < 0.001), 12 (43.1% vs. 28.4%, p? < 0.001), and 24 months (40.4% vs. 33.3%, p? < 0.001). Veterans were more likely to have? = 180 days of supply if they were older, exempt from medication copays, used other medications with significant weight-gain, significant weight-loss, or modest weight-loss side effects, or resided in the West North Central or Pacific regions. Veterans were less likely to have? = 180 days of AOM supply if they had diabetes or initiated MOVE! later in the study period. CONCLUSIONS: AOM use following MOVE! initiation was uncommon, and exposure was time-limited. AOM?+?MOVE! was associated with a higher probability of achieving clinically significant weight loss than MOVE! alone.